FlexGen is a biotechnology company based in Leiden, Netherlands. FlexGen is a spin-off from Leiden University Medical Centre and Dutch Space and has proprietary technologies for laser based in-situ synthesis of oligonucleotides and other biomolecules. Wikipedia.
McGinn S.,French Atomic Energy Commission |
Bauer D.,University of Oxford |
Brefort T.,Comprehensive Biomarker Center GmbH |
Dong L.,University of Oxford |
And 70 more authors.
New Biotechnology | Year: 2016
The REvolutionary Approaches and Devices for Nucleic Acid analysis (READNA) project received funding from the European Commission for 41/2 years. The objectives of the project revolved around technological developments in nucleic acid analysis. The project partners have discovered, created and developed a huge body of insights into nucleic acid analysis, ranging from improvements and implementation of current technologies to the most promising sequencing technologies that constitute a 3rd and 4th generation of sequencing methods with nanopores and in situ sequencing, respectively. © 2015.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH-2007-1.1-3 | Award Amount: 15.75M | Year: 2008
The REvolutionary Approaches and Devices for Nucleic Acid analysis READNA consortium is composed of researchers from 10 academic institutions, 5 SMEs and 3 large companies. The goals of the READNA consortium are to revolutionize nucleic acid analysis methods, by 1) improving elements necessary to use the currently emerging generation of nucleic acid sequencers in a meaningful and accessible way, 2) providing methods that allow in situ nucleic acid analysis and methods capable of selectively characterizing mutant DNA in a high background of wildtype DNA, 3) combining RNA and DNA analysis in a single analytical device, 4) providing technology to efficiently analyze DNA methylation (genome-wide, with high resolution and in its long-range context), 5) implementing novel concepts for high-throughput HLA-screening, 6) developing fully integrated solutions for mutational screening of small target regions (such as for screening newborns for cystic fibrosis mutations), 7) developing a device for screening multiple target regions with high accuracy, and 8) implementing strategies for effective and high-resolution genotyping of copy number variations. An important part of READNA is dedicated to the development of the next generation of nucleic analysis devices on individual DNA molecules by stretching out nucleic acid molecules in nanosystems, using alpha-hemolysing nanopores and carbon nanotubes. These approaches will benefit from improved interrogation and detection strategies which we will develop. Our methods and devices will boost the possibilities of genetic research by closing in on the target of 1000 Euros for the sequence of a complete human genome, while at the same time leading a revolution in cost-effective, non-invasive early screening for diseases such as cancer.
PubMed | Comprehensive Biomarker Center GmbH, PHOTONIS France S.A.S. Avenue Roger Roncier, Chalmers University of Technology, Max Planck Institute for Molecular Genetics and 20 more.
Type: Journal Article | Journal: New biotechnology | Year: 2016
The REvolutionary Approaches and Devices for Nucleic Acid analysis (READNA) project received funding from the European Commission for 41/2 years. The objectives of the project revolved around technological developments in nucleic acid analysis. The project partners have discovered, created and developed a huge body of insights into nucleic acid analysis, ranging from improvements and implementation of current technologies to the most promising sequencing technologies that constitute a 3(rd) and 4(th) generation of sequencing methods with nanopores and in situ sequencing, respectively.
Franssen-Van Hal N.L.W.,FlexGen |
Van Der Putte P.,FlexGen |
Hellmuth K.,FlexGen |
Matysiak S.,FlexGen |
And 2 more authors.
Analytical Chemistry | Year: 2013
Aptamer microarrays are a promising high-throughput method for ultrasensitive detection of multiple analytes, but although much is known about the optimal synthesis of oligonucleotide microarrays used in hybridization-based genomics applications, the bioaffinity interactions between aptamers and their targets is qualitatively different and requires significant changes to synthesis parameters. Focusing on streptavidin-binding DNA aptamers, we employed light-directed in situ synthesis of microarrays to analyze the effects of sequence fidelity, linker length, surface probe density, and substrate functionalization on detection sensitivity. Direct comparison with oligonucleotide hybridization experiments indicates that aptamer microarrays are significantly more sensitive to sequence fidelity and substrate functionalization and have different optimal linker length and surface probe density requirements. Whereas microarray hybridization probes generate maximum signal with multiple deletions, aptamer sequences with the same deletion rate result in a 3-fold binding signal reduction compared with the same sequences synthesized for maximized sequence fidelity. The highest hybridization signal was obtained with dT 5mer linkers, and the highest aptamer signal was obtained with dT 11mers, with shorter aptamer linkers significantly reducing the binding signal. The probe hybridization signal was found to be more sensitive to molecular crowding, whereas the aptamer probe signal does not appear to be constrained within the density of functional surface groups commonly used to synthesize microarrays. © 2013 American Chemical Society.